Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sorensen, 2008, Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma, Br J Cancer, 99, 44, 10.1038/sj.bjc.6604421
Byrne, 1999, Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study, J Clin Oncol, 17, 25, 10.1200/JCO.1999.17.1.25
Novak, 2002, A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma, Br J Cancer, 87, 491, 10.1038/sj.bjc.6600505
Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136
Favaretto, 2003, Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study, Cancer, 97, 2791, 10.1002/cncr.11405
Ceresoli, 2006, Phase II study of Pemetrexed plus Carboplatin in malignant pleural mesothelioma, J Clin Oncol, 24, 1443, 10.1200/JCO.2005.04.3190
Santoro, 2008, Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program, J Thorac Oncol, 3, 756, 10.1097/JTO.0b013e31817c73d6
Manegold, 2005, Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma, Ann Oncol, 16, 923, 10.1093/annonc/mdi187
Vogelzang, 1999, Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?, J Clin Oncol, 17, 2626
Giaccone, 2002, Phase II trial of ZD0473 as second-line therapy in mesothelioma, Eur J Cancer, 38, S19, 10.1016/S0959-8049(02)80018-1
Fizazi, 2003, Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study, J Clin Oncol, 21, 349, 10.1200/JCO.2003.05.123
Porta, 2005, Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients, Lung Cancer, 48, 429, 10.1016/j.lungcan.2004.11.015
Jänne, 2006, Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program, J Thorac Oncol, 1, 506, 10.1097/01243894-200607000-00002
Sorensen, 2007, Pemetrexed as second-line treatment in malignant pleural mesothelioma (MPM) after platinum-based first-line treatment, J Thorac Oncol, 2, 147, 10.1097/JTO.0b013e31802f3813
Fennell, 2007, Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma, Cancer, 109, 93, 10.1002/cncr.22366
Zucali, 2008, Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma, Cancer, 112, 1555, 10.1002/cncr.23337
Ceresoli, 2010, Second-line treatment for malignant pleural mesothelioma, Cancer Treat Rev, 36, 24, 10.1016/j.ctrv.2009.09.003
Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887
Curran, 1998, Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145
Scherpereel, 2010, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, 35, 479, 10.1183/09031936.00063109
Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059
Gore, 1990, Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds, Gynecol Oncol, 36, 207, 10.1016/0090-8258(90)90174-J
Ceresoli, 2011, Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma, Lung Cancer, 72, 73, 10.1016/j.lungcan.2010.12.004
Kaplan, 1958, Nonparametric estimation of incomplete observations, J Am Stat Assoc, 53, 457, 10.2307/2281868
Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X
Taylor, 2008, Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program, J Thorac Oncol, 3, 764, 10.1097/JTO.0b013e31817c73ec
Harvey, 1984, Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin, Cancer, 54, 961, 10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B
Hoffman, 1996, Paclitaxel and carboplatin combination chemotherapy is an effective palliative treatment for malignant mesothelioma, Proc Am Soc Clin Oncol
Karthaus, 2005, Second line chemotherapy for patients with malignant mesothelioma (MPM) pretreated with pemetrexed and platinum, J Clin Oncol, 23, 7331, 10.1200/jco.2005.23.16_suppl.7331
Zucali, 2009, Future developments in the management of malignant pleural mesothelioma, Expert Rev Anticancer Ther, 9, 453, 10.1586/era.09.2
Pfisterer, 2006, Management of platinum-sensitive recurrent ovarian cancer, Semin Oncol, 33, S12, 10.1053/j.seminoncol.2006.03.012
Razak, 2008, Re-treatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option, Lung Cancer, 60, 294, 10.1016/j.lungcan.2007.08.031
Serke, 2007, Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma, J Clin Oncol, 25, 18198, 10.1200/jco.2007.25.18_suppl.18198
Hayashi, 2010, Re-treatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed, Int J Clin Oncol, 15, 497, 10.1007/s10147-010-0064-7